ASCO 2021: low-cost, me-too TKIs as new options for EGFR+ NSCLC,

The randomised Phase III trial, AENEAS, included previously untreated … The drug is co-developed with Hansoh Pharma in China, with Hansoh …, The randomised Phase III trial, AENEAS, included previously untreated … The drug is co-developed with Hansoh Pharma in China, with Hansoh …, Read More

Scroll to Top